Muscle_fibers,_skeletal

3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

BACKGROUND

Sarcopenia is a chronic degenerative condition characterized by the progressive loss of muscle mass and function. Current therapeutic strategies exhibit limited therapeutic efficacy and present substantial challenges in ensuring sustained patient compliance. Although mitochondrial dysfunction is a confirmed biomarker of...

🗓️ 2026-06-18
📰 Publication: Phytomedicine
Read More3,3'-Diindolylmethane ameliorates muscle atrophy by modulating mitochondrial function and calcium homeostasis.

RNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Evidence identifies proteostasis imbalance and oxidative stress serve as fundamental pathological hallmarks of muscular atrophy, yet ring finger protein 10 (RNF10), a novel E3 ubiquitin ligase, in age-related muscular atrophy remains poorly characterized. Employing a natural aging mouse model and...

🗓️ 2026-06-18
📰 Publication: Free Radical Biology And Medicine
Read MoreRNF10 Attenuates Age-Related Muscle Atrophy by Promoting p53 Degradation and Alleviating Oxidative Stress.

Hepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

A bidirectional relationship exists between metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), and sarcopenia, with each worsening the prevalence and prognosis of the other. Hepatokines have recently been shown to affect skeletal...

🗓️ 2026-06-11
📰 Publication: Molecular Metabolism
Read MoreHepatokines lipocalin 2 and osteopontin drive muscle atrophy in MASH.

Micheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

BACKGROUND

Cancer cachexia profoundly impacts patient survival and quality of life. Current treatments fail to halt this trajectory, highlighting an urgent clinical need for host-directed therapies capable of uncoupling skeletal muscle wasting from tumor progression. This study investigated the therapeutic potential...

🗓️ 2026-05-06
📰 Publication: Microbiome
Read MoreMicheliolide ameliorates colon cancer cachexia by modulating gut microbiota-immune signaling via Phocaeicola vulgatus enrichment.

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4-Mediated Mitochondrial Restoration and Inflammation Suppression.

BACKGROUND

Peripheral nerve injury-induced muscle atrophy shares core pathophysiological features with systemic wasting disorders including cachexia and sarcopenia, yet early molecular triggers remain undefined. This study investigates the pathogenic role of receptor-interacting protein kinase 3 (RIPK3) in denervation atrophy.

METHODS

Sciatic denervation was...

🗓️ 2026-05-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4-Mediated Mitochondrial Restoration and Inflammation Suppression.

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

BACKGROUND

Patients with end-stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not...

🗓️ 2026-04-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSystemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

Cancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

BACKGROUND

Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific...

🗓️ 2026-04-24
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

MCC950-Loaded M12-Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis-Induced Muscle Atrophy.

BACKGROUND

Sepsis-induced myopathy (SIM) is a severe complication that contributes to late-stage mortality and functional impairment in sepsis patients. The NLRP3 inflammasome plays a pivotal role in the pathogenesis of SIM, and its selective inhibitor MCC950 has shown promising therapeutic potential....

🗓️ 2026-04-15
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMCC950-Loaded M12-Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis-Induced Muscle Atrophy.

Mitochondrial Permeability Transition in Skeletal Muscle Phenocopies Muscle Alterations seen in Cancer Cachexia and other Wasting Conditions.

BACKGROUND

Skeletal muscle in wasting conditions often exhibits a common set of phenotypes that include atrophy, mitochondrial respiratory dysfunction, and fragmentation of the acetylcholine receptor (AChR) cluster at the endplate. Mitochondria are frequently implicated in driving muscle pathology in these conditions,...

🗓️ 2026-02-23
Read MoreMitochondrial Permeability Transition in Skeletal Muscle Phenocopies Muscle Alterations seen in Cancer Cachexia and other Wasting Conditions.

CXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

BACKGROUND

Advanced metastasis produces cachexia, a complex skeletal muscle wasting syndrome that accounts for one-third of patient deaths. There is currently no approved drug therapy for cancer cachexia. Cancer-associated fibroblasts (CAF) within tumors have been hypothesized to contribute to cachexia, but...

🗓️ 2025-12-15
📰 Publication: Journal Of Biomedical Science
Read MoreCXCL5 neutralization mitigates cancer cachexia by disrupting CAF-cancer cell crosstalk.

Chinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis and autophagy via AMPK and maintaining myosin homeostasis.

Sarcopenia, a prevalent age-related degenerative disorder, poses significant challenges in geriatric care. Chinese leek demonstrates therapeutic potential against sarcopenia progression, with emerging evidence suggesting its extracellular vesicles (EVs) may mediate these effects. Notably, plant-derived EVs have garnered increasing attention due...

🗓️ 2025-11-20
📰 Publication: Journal Of Nanobiotechnology
Read MoreChinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis and autophagy via AMPK and maintaining myosin homeostasis.

STX4 Is Indispensable for Mitochondrial Homeostasis in Skeletal Muscle.

BACKGROUND

Mitochondrial homeostasis is vital for optimal skeletal muscle integrity. Mitochondrial quality control (MQC) mechanisms that are essential for maintaining proper functions of mitochondria include mitochondrial biogenesis, dynamics and mitophagy. Previously, Syntaxin 4 (STX4), traditionally considered a cell surface protein known...

🗓️ 2025-11-11
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSTX4 Is Indispensable for Mitochondrial Homeostasis in Skeletal Muscle.

An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

BACKGROUND

Cystinosis is a rare multisystem, autosomal recessive disease caused by dysfunction or loss of cystinosin (CTNS), which results in lysosomal cystine accumulation, primarily affecting the kidneys. Advances in renal transplantation, cysteamine treatment and improved medical care have increased life expectancy,...

🗓️ 2025-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAn Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins.

PRDX5 Regulates Mitochondrial Function and Nuclear Spreading in Myogenesis and Acts With PRDX3 to Delay Muscle Aging.

BACKGROUND

Skeletal muscle aging is associated with oxidative stress and mitochondrial dysfunction. Peroxiredoxins (PRDXs), particularly PRDX3 and PRDX5, are antioxidant enzymes that are uniquely localized to mitochondria. While PRDX3 has been reported to play a role in maintaining mitochondrial function in...

🗓️ 2025-10-28
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePRDX5 Regulates Mitochondrial Function and Nuclear Spreading in Myogenesis and Acts With PRDX3 to Delay Muscle Aging.

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

BACKGROUND

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of survival of motor neuron (SMN) protein inducing progressive muscle weakness and atrophy due to motor neurons degeneration. Despite benefits of SMN restoration therapies in patients, motor defects are...

🗓️ 2025-10-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDrug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!